OSBPL3 drives colorectal cancer progression via Hippo-YAP signaling and modulates MEK inhibitor sensitivity
Colorectal cancer progression involves dysregulated signaling pathways such as Hippo-YAP, but upstream regulators remain poorly defined. Here we demonstrate that oxysterol-binding protein-like 3 (OSBPL3) modulates Hippo-YAP signaling to drive tumor aggressiveness. Analysis of clinical specimens and experimental models shows that elevated OSBPL3 levels in colorectal cancer tissues correlate with shortened patient survival. Depleting OSBPL3 impairs cancer cell proliferation and invasion and induces cell cycle arrest, while its overexpression accelerates tumor growth. Mechanistic studies reveal that OSBPL3 binds 14-3-3 proteins to promote YAP1 nuclear translocation, activating downstream oncogenic pathways. Notably, tumors with high OSBPL3 expression exhibit resistance to MEK inhibitors, but this resistance is overcome by YAP1 suppression or combined YAP/MEK inhibition in patient-derived organoids. These results establish OSBPL3 as a critical Hippo-YAP pathway regulator and propose targeting OSBPL3-mediated signaling as a therapeutic strategy for colorectal cancers with Hippo pathway alterations.
Authors
- Chaojing Zheng (ORCID: https://orcid.org/0000-0002-1306-6311)
- Yuchen Zhong (ORCID: https://orcid.org/0000-0002-8643-2052)
- Hongyu Wu (ORCID: https://orcid.org/0000-0001-7503-2734)
- Qian Zhang (ORCID: https://orcid.org/0000-0003-4928-3366)
- Weiyuan Zhang
- Z. Yuan
- Chenkai Zhang
- Guiyu Wang
- Hanqing Hu
- Chunlin Wang
- Meng Wang
- Jun Luo
- Hao Zhang
Institutions
- Fujian Medical University (CN)
- Harbin Medical University (CN)
- Zhejiang Cancer Hospital (CN)
- Second Affiliated Hospital of Harbin Medical University (CN)
- Union Hospital (CN)
- Hangzhou Medical College (CN)
Publication Details
- Journal
- Communications Biology
- Published
- 2026-03-07
- DOI
- https://doi.org/10.1038/s42003-026-09811-8
- Primary Topic
- Hippo pathway signaling and YAP/TAZ
- Type
- article
- Field-Weighted Citation Impact
- 0.00